All In Biotech

Drug Trial Radar · NCT01491815

Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction

A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatment

Last checked: Nov 19, 2026Latest source record: Jul 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 812 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

812

Actual

Start

Dec 14, 2012

Primary completion

Jul 2023

Study completion Dec 2023

Sponsor

Lead sponsor
Karolinska InstitutetAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 14, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an international (Sweden, Finland, Norway, Denmark, Iceland and the Netherlands) trial designed to compare the safety and efficacy of active conventional therapy (ACT) and three biologic treatments in subjects with early rheumatoid arthritis (RA). The global aim of this study is to assess and compare 1. the proportion of subjects who achieve remission with ACT versus three different biologic therapies (Certolizumab-pegol, Abatacept or Tocilizumab) 2. two alternative de-escalation strategies in patients who respond to first-line therapy.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Non-biological DMARD'sDrug

    Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, Iceland, and the Netherlands)

  • CimziaBiological

    Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week

  • OrenciaBiological

    Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week

  • RoActemraBiological

    Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients in remission at week 24 from baseline according to CDAITime frame: 24 weeks from BL
  2. The proportion of patients in remission at week 24 after dose-reduction according to CDAITime frame: 24 weeks after dose-reduction
  3. The radiographic progression of total Sharp van der Heijde score after 48 weeks from baselineTime frame: 48 weeks from BL

Locations

30 sites in 6 countries. Site status is shown where the registry gives one.

  • Aalborg University Hospital

    Aalborg, Denmark

  • Aarhus University Hospital

    Aarhus, Denmark

  • Rigshospitalet

    Copenhagen, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Silkeborg University Clinic

    Silkeborg, Denmark

  • University Hospital of Southern Denmark

    Sønderborg, Denmark

  • Svendborg Hospital OUH

    Svendborg, Denmark

  • Helsinki University Central Hospital

    Helsinki, Finland

  • Central Finland Central Hospital

    Jyväskylä, Finland

  • Kuopio University Hospital

    Kuopio, Finland

  • Tampere University Hospital

    Tampere, Finland

  • Landspitali University Hospital

    Reykjavik, Iceland

  • Reade

    Amsterdam, Netherlands

  • Ålesund Hospital

    Ålesund, Norway

  • Haukeland University Hospital

    Bergen, Norway

  • Diakonhjemmet Hospital

    Oslo, Norway

  • University Hospital of North Norway

    Tromsø, Norway

  • St. Olav's Hospital

    Trondheim, Norway

  • Falu Hospital

    Falun, Sweden

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

  • The Karolinska University Hospital

    Huddinge, Sweden

  • Linköping University Hospital

    Linköping, Sweden

  • Skåne University Hospital

    Lund, Sweden

  • Skåne University Hospital

    Malmö, Sweden

  • Örebro University Hospital

    Örebro, Sweden

  • The Karolinska University Hospital

    Solna, Sweden

  • Academic Specialist Center

    Stockholm, Sweden

  • The Karolinska Institutet

    Stockholm, Sweden

  • Uppsala University Hospital

    Uppsala, Sweden

  • Västmanlands Hospital

    Västerås, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.